Farther Finance Advisors LLC Buys 3,158 Shares of Amgen Inc. $AMGN

Farther Finance Advisors LLC increased its stake in Amgen Inc. (NASDAQ:AMGN) by 22.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,035 shares of the medical research company’s stock after buying an additional 3,158 shares during the quarter. Farther Finance Advisors LLC’s holdings in Amgen were worth $4,807,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Laurel Wealth Advisors LLC boosted its stake in shares of Amgen by 27,765.8% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after purchasing an additional 6,676,575 shares during the period. Norges Bank purchased a new position in shares of Amgen during the second quarter valued at approximately $1,663,726,000. Vanguard Group Inc. boosted its position in shares of Amgen by 1.6% during the second quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after buying an additional 841,117 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Amgen by 5.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after buying an additional 687,735 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Amgen by 128.9% in the first quarter. The Manufacturers Life Insurance Company now owns 1,065,694 shares of the medical research company’s stock worth $332,017,000 after buying an additional 600,096 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Up 0.3%

Shares of Amgen stock opened at $332.50 on Thursday. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. The stock has a market cap of $179.04 billion, a price-to-earnings ratio of 25.70, a PEG ratio of 3.08 and a beta of 0.45. The firm’s 50-day moving average is $321.56 and its two-hundred day moving average is $301.12. Amgen Inc. has a 1 year low of $257.05 and a 1 year high of $346.38.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The firm had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. During the same quarter in the prior year, the company earned $5.58 EPS. The company’s revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a $2.52 dividend. The ex-dividend date is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. This is a boost from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is 73.57%.

Analyst Ratings Changes

A number of brokerages recently issued reports on AMGN. Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. Piper Sandler increased their target price on Amgen from $342.00 to $381.00 and gave the stock an “overweight” rating in a research note on Friday, November 14th. Guggenheim boosted their target price on shares of Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Daiwa Capital Markets upped their price target on shares of Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Amgen has an average rating of “Moderate Buy” and an average target price of $332.85.

Insider Transactions at Amgen

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the transaction, the executive vice president owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 10,908 shares of company stock valued at $3,674,966. Corporate insiders own 0.76% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.